Evidence map›Paper›PMID 39739260›Full record

ArticleAnnals of surgical oncology2025

Enhancing the Immunotherapeutic Effect by IP-001 and Irreversible Electroporation in Mouse Oligometastatic Models of Pancreatic Adenocarcinoma.

Yan Li, Samuel S K Lam, Yonglin Gao, Emily Shore, David W Anderson, Tomas Hode, Robert C Martin

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yan LiDivision of Surgical Oncology, Department of Surgery, School of Medicine, University of Louisville, Louisville, KY, USA. Yan.li@louisville.edu.
Samuel S K LamImmunophotonics Inc, St. Louis, MO, USA.
Yonglin GaoDivision of Surgical Oncology, Department of Surgery, School of Medicine, University of Louisville, Louisville, KY, USA.
Emily ShoreDivision of Surgical Oncology, Department of Surgery, School of Medicine, University of Louisville, Louisville, KY, USA.
David W AndersonImmunophotonics Inc, St. Louis, MO, USA.
Tomas HodeImmunophotonics Inc, St. Louis, MO, USA.
Robert C MartinDivision of Surgical Oncology, Department of Surgery, School of Medicine, University of Louisville, Louisville, KY, USA. robert.martin@louisville.edu.

Funding

Role of oxidized linoleic acid metabolites in the pathogenesis of alcoholic liver diseaseP20GM113226 · NIGMS · UNIVERSITY OF LOUISVILLE · PI MCCLAIN, CRAIG J. · 2016 to 2025
$24.1M
Institutional Development Award (IDeA) from the NIGMS of the National Institutes of Health P20GM113226National Institutes of Health from the R44 Small Business Innovation Research Grant CA257683-01A1
6 · The paper itself

Abstract

backgroundThis study aimed to evaluate the immunotherapeutic effect of irreversible electroporation (IRE) and IP-001 in pancreatic adenocarcinoma with metastasis.

methodsOrthotopic models of pancreatic adenocarcinoma with hepatic oligometastasis were established by implantation of tumor tissues (derived from Pan02 or KPC cells) size 2 mm

resultsIn the KPC oligometastatic model, IRE+IP-001 therapy significantly suppressed the growth of oligometastatic tumor. Flow cytometry showed significantly increased tumor-infiltrating lymphocytes (TILs) (e.g., CD8

conclusionThe study provided compelling evidence for the efficacy of IRE&IP-001 therapy in suppressing pancreatic tumors, including off-target oligometastatic lesions. The observed off-target effect underscores the importance of systemic immune activation in achieving effective tumor control.

Indexed as

AdenocarcinomaElectroporationImmune Checkpoint InhibitorsImmunotherapyLiver NeoplasmsPancreatic NeoplasmsAnimalsCombined Modality TherapyDisease Models, AnimalHumansLymphocytes, Tumor-InfiltratingMiceMice, Inbred C57BLTumor Cells, CulturedImmune Checkpoint InhibitorsImmune-modulationIP-001Irreversible electroporationN‐dihydrogalactochitosanPancreatic adenocarcinoma

Identifiers

PMID39739260

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.